Metabolic alterations in a rat model of takotsubo syndrome.


Journal

Cardiovascular research
ISSN: 1755-3245
Titre abrégé: Cardiovasc Res
Pays: England
ID NLM: 0077427

Informations de publication

Date de publication:
29 06 2022
Historique:
received: 17 07 2020
accepted: 09 03 2021
pubmed: 13 3 2021
medline: 1 7 2022
entrez: 12 3 2021
Statut: ppublish

Résumé

Cardiac energetic impairment is a major finding in takotsubo patients. We investigate specific metabolic adaptations to direct future therapies. An isoprenaline-injection female rat model (vs. sham) was studied at Day 3; recovery assessed at Day 7. Substrate uptake, metabolism, inflammation, and remodelling were investigated by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography, metabolomics, quantitative PCR, and western blot (WB). Isolated cardiomyocytes were patch-clamped during stress protocols for redox states of NAD(P)H/FAD or [Ca2+]c, [Ca2+]m, and sarcomere length. Mitochondrial respiration was assessed by seahorse/Clark electrode (glycolytic and β-oxidation substrates). Cardiac 18F-FDG metabolic rate was increased in takotsubo (P = 0.006), as was the expression of GLUT4-RNA/GLUT1/HK2-RNA and HK activity (all P < 0.05), with concomitant accumulation of glucose- and fructose-6-phosphates (P > 0.0001). Both lactate and pyruvate were lower (P < 0.05) despite increases in LDH-RNA and PDH (P < 0.05 both). β-Oxidation enzymes CPT1b-RNA and 3-ketoacyl-CoA thiolase were increased (P < 0.01) but malonyl-CoA (CPT-1 regulator) was upregulated (P = 0.01) with decreased fatty acids and acyl-carnitines levels (P = 0.0001-0.02). Krebs cycle intermediates α-ketoglutarate and succinyl-carnitine were reduced (P < 0.05) as was cellular ATP reporter dihydroorotate (P = 0.003). Mitochondrial Ca2+ uptake during high workload was impaired on Day 3 (P < 0.0001), inducing the oxidation of NAD(P)H and FAD (P = 0.03) but resolved by Day 7. There were no differences in mitochondrial respiratory function, sarcomere shortening, or [Ca2+] transients of isolated cardiomyocytes, implying preserved integrity of both mitochondria and cardiomyocyte. Inflammation and remodelling were upregulated-increased CD68-RNA, collagen RNA/protein, and skeletal actin RNA (all P < 0.05). Dysregulation of glucose and lipid metabolic pathways with decreases in final glycolytic and β-oxidation metabolites and reduced availability of Krebs intermediates characterizes takotsubo myocardium. The energetic deficit accompanies defective Ca2+ handling, inflammation, and upregulation of remodelling pathways, with the preservation of sarcomeric and mitochondrial integrity.

Identifiants

pubmed: 33711093
pii: 6169160
doi: 10.1093/cvr/cvab081
pmc: PMC9239582
doi:

Substances chimiques

Fatty Acids 0
NAD 0U46U6E8UK
Fluorodeoxyglucose F18 0Z5B2CJX4D
Flavin-Adenine Dinucleotide 146-14-5
Malonyl Coenzyme A 524-14-1
RNA 63231-63-0
Glucose IY9XDZ35W2
Calcium SY7Q814VUP

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1932-1946

Subventions

Organisme : British Heart Foundation
ID : FS/16/39/32174
Pays : United Kingdom
Organisme : British Heart Foundation
ID : NH/19/1/34595
Pays : United Kingdom
Organisme : British Heart Foundation
ID : PG/18/35/33786
Pays : United Kingdom
Organisme : British Heart Foundation
ID : FS/RTF/20/30009
Pays : United Kingdom
Organisme : British Heart Foundation
ID : CS/17/4/32960
Pays : United Kingdom
Organisme : British Heart Foundation
ID : PG/15/88/31780
Pays : United Kingdom
Organisme : British Heart Foundation
ID : PG/17/64/33205
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.

Références

Atherosclerosis. 2005 Jan;178(1):67-73
pubmed: 15585202
J Am Coll Cardiol. 2012 Jan 10;59(2):153-63
pubmed: 22222080
Cell Rep. 2015 Jul 7;12(1):15-22
pubmed: 26119742
Exp Physiol. 2006 May;91(3):571-80
pubmed: 16452123
Methods Mol Biol. 2007;357:271-96
pubmed: 17172694
J Am Coll Cardiol. 2003 Mar 5;41(5):743-8
pubmed: 12628716
Eur Heart J. 2013 Feb;34(5):397
pubmed: 22922294
J Mol Cell Cardiol. 1997 Jun;29(6):1675-85
pubmed: 9220353
Circulation. 2010 Nov 30;122(22):2273-80
pubmed: 21098439
J Am Coll Cardiol. 2017 Aug 22;70(8):975-991
pubmed: 28818208
J Vis Exp. 2015 Oct 30;(105):e53216
pubmed: 26555567
Int J Cardiol. 2010 Oct 8;144(2):212-8
pubmed: 19443060
Cell Rep. 2015 Jul 7;12(1):23-34
pubmed: 26119731
Circulation. 2019 Mar 26;139(13):1581-1592
pubmed: 30586731
PLoS One. 2017 Oct 19;12(10):e0186656
pubmed: 29049352
Biochem J. 1993 Oct 1;295 ( Pt 1):287-93
pubmed: 8216230
Eur J Heart Fail. 2013 Jan;15(1):9-22
pubmed: 23099354
Circulation. 2018 Mar 6;137(10):1039-1048
pubmed: 29128863
Proc Natl Acad Sci U S A. 1991 Mar 15;88(6):2525-9
pubmed: 1706526
PLoS One. 2012;7(7):e40221
pubmed: 22844400
Circ Res. 1997 Jan;80(1):82-7
pubmed: 8978326
Biophys J. 2003 Apr;84(4):2734-55
pubmed: 12668482
Cardiovasc Res. 1999 Apr;42(1):246-53
pubmed: 10435017
J Nucl Med. 2006 Nov;47(11):1891-900
pubmed: 17079824
Int J Cardiol. 2015;189:112-4
pubmed: 25889440
Anal Chem. 2009 Aug 15;81(16):6656-67
pubmed: 19624122
J Pathol. 2003 Mar;199(3):387-97
pubmed: 12579541
Int J Cardiol. 2013 Oct 3;168(3):1943-50
pubmed: 23357048
Cell Metab. 2015 Sep 1;22(3):472-84
pubmed: 26256392
J Mol Cell Cardiol. 2011 Jan;50(1):230-8
pubmed: 20971119
Eur Heart J. 2007 Nov;28(21):2598-604
pubmed: 17921529
Circ Res. 2018 May 11;122(10):1460-1478
pubmed: 29748369
JACC Basic Transl Sci. 2018 Apr 18;3(2):213-226
pubmed: 30062207
N Engl J Med. 2015 Sep 3;373(10):929-38
pubmed: 26332547
Br J Pharmacol. 2014 Apr;171(8):2080-90
pubmed: 24147975
J Am Soc Echocardiogr. 2017 Aug;30(8):745-755
pubmed: 28599831
JACC Basic Transl Sci. 2018 Dec 31;3(6):766-778
pubmed: 30623136
J Biol Chem. 1989 Aug 15;264(23):13430-9
pubmed: 2503501
Circ Res. 2012 Sep 14;111(7):863-75
pubmed: 22777004
Circulation. 2012 Nov 20;126(21):e324-6
pubmed: 23169256
Cell Metab. 2011 Apr 6;13(4):461-468
pubmed: 21459330
Circ Res. 2006 Jul 21;99(2):172-82
pubmed: 16778127

Auteurs

Nadine Godsman (N)

Aberdeen Cardiovascular and Diabetes Centre, University of Aberdeen, Polwarth Building, Foresterhill, Aberdeen AB25 2ZD, UK.

Michael Kohlhaas (M)

Comprehensive Heart Failure Center (CHFC), Würzburg, Deutsches Zentrum für Herzinsuffizienz Würzburg, Universitätsklinikum Würzburg, Am Schwarzenberg 15, Haus A15, 97078 Würzburg, Germany.

Alexander Nickel (A)

Comprehensive Heart Failure Center (CHFC), Würzburg, Deutsches Zentrum für Herzinsuffizienz Würzburg, Universitätsklinikum Würzburg, Am Schwarzenberg 15, Haus A15, 97078 Würzburg, Germany.

Lesley Cheyne (L)

Aberdeen Cardiovascular and Diabetes Centre, University of Aberdeen, Polwarth Building, Foresterhill, Aberdeen AB25 2ZD, UK.

Marco Mingarelli (M)

Biomedical Physics, University of Aberdeen, Aberdeen AB25 2ZD, UK.

Lutz Schweiger (L)

John Mallard Scottish P.E.T. Centre, University of Aberdeen, Aberdeen AB25 2ZD, UK.

Claire Hepburn (C)

Aberdeen Cardiovascular and Diabetes Centre, University of Aberdeen, Polwarth Building, Foresterhill, Aberdeen AB25 2ZD, UK.

Chantal Munts (C)

School for Cardiovascular Diseases, Faculty of Health, Medicine and Life Sciences - Maastricht University, Universiteitssingel 40, 6229 ER Maastricht, Netherlands.

Andy Welch (A)

Biomedical Physics, University of Aberdeen, Aberdeen AB25 2ZD, UK.

Mirela Delibegovic (M)

Aberdeen Cardiovascular and Diabetes Centre, University of Aberdeen, Polwarth Building, Foresterhill, Aberdeen AB25 2ZD, UK.

Marc Van Bilsen (M)

School for Cardiovascular Diseases, Faculty of Health, Medicine and Life Sciences - Maastricht University, Universiteitssingel 40, 6229 ER Maastricht, Netherlands.

Christoph Maack (C)

Comprehensive Heart Failure Center (CHFC), Würzburg, Deutsches Zentrum für Herzinsuffizienz Würzburg, Universitätsklinikum Würzburg, Am Schwarzenberg 15, Haus A15, 97078 Würzburg, Germany.

Dana K Dawson (DK)

Aberdeen Cardiovascular and Diabetes Centre, University of Aberdeen, Polwarth Building, Foresterhill, Aberdeen AB25 2ZD, UK.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH